Mycophenolate Mofetil · Regulatory label update

FDA supplemental approval: Cellcept (Labeling)

U.S. Food and Drug Administration · July 29, 2026

Regulatory Update Why this matters to you Expert discussion

An action by a regulator. Authoritative on labelling and availability.

AI Summary

The FDA approved a supplemental labeling change for CellCept (mycophenolate mofetil) 500 mg tablets on 29 July 2026. This record confirms a regulatory action but contains no information about the specific labeling modification, clinical efficacy, safety data, or trial results.

What was studied

Regulatory label update.

Key findings

Safety

No safety or efficacy data are reported; this is a regulatory action summary only.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

This is an FDA supplemental approval action for a labeling change to an established immunosuppressant; it does not report clinical trial outcomes or comparative efficacy.

Reported figures

Quoted from the source exactly as published.

Approval date2026-07-29

Dose strength500 mg

Caveats

This record does not contain clinical trial results, efficacy data, or comparative outcomes.
The specific content of the labeling change is not described in this record.
No safety or efficacy data are reported; this is a regulatory action summary only.
The indication(s) and population affected by the labeling change are not specified in this record.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

This is a regulatory action, not a clinical study.

Directness

insufficient

Regulatory record does not report clinical trial data or patient outcomes.

Consistency

insufficient

No comparative or outcome data provided in this record.

Risk of bias

insufficient

Not applicable to a regulatory labeling submission.

Sample adequacy

insufficient

No study population or sample reported in this record.

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Drugs@FDA record for application NDA050723. This is a regulatory action record, not a clinical study. Brand name: CELLCEPT. Active ingredient: MYCOPHENOLATE MOFETIL. Sponsor: ROCHE PALO. Submission type: SUPPL (supplement). Submission class: Labeling. Approval status date: 2026-07-29. Products: CELLCEPT, TABLET, ORAL, MYCOPHENOLATE MOFETIL 500MG.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Mycophenolate MofetilRoche Palo